2019 Plenary Keynotes

Bispecific, Soluble TCR as the Next Therapeutic Platform
Bahija Jallal, PhD, CEO and Director of the Board, Immunocore
Attacking Cancer Cell Surfaceomes with Recombinant Antibodies
James A. Wells, PhD, Professor, Departments of Pharmaceutical Chemistry and Cellular & Molecular Pharmacology, University of California, San Francisco
Choose your language
Japanese
Traditional Chinese
Simplified Chinese
Korean